{"entity":{"id":"nct07415525","kind":"trial","name":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of IBI343 in pancreatic cancer, run by Zhejiang University, not yet recruiting.","summary":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT07415525 by Zhejiang University, with a registry enrolment figure of 40 participants, started 2026-02-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: IBI343. Conditions listed: Pancreatic Cancer; Borderline Resectable Pancreatic Adenocarcinoma. Primary outcome: 12-month Event-Free Survival (EFS) rate. Pancreatic eligibility wording from the registry: \"* (2)Histopathologically confirmed pancreatic adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07415525","url":"https://clinicaltrials.gov/study/NCT07415525"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["ibi343"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07415525","phase":"2","setting":"A Phase II Clinical Study Evaluating the Safety and Efficacy of IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Subjects With Borderline Resectable Pancreatic Cancer","sponsor":"Zhejiang University","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07415525/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"ibi343","kind":"drug","name":"IBI343","route":"/drugs/ibi343/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}